BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32864325)

  • 1. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.
    Davis AK; Barrett FS; Griffiths RR
    J Contextual Behav Sci; 2020 Jan; 15():39-45. PubMed ID: 32864325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color.
    Davis AK; Xin Y; Sepeda ND; Garcia-Romeu A; Williams MT
    Chronic Stress (Thousand Oaks); 2021; 5():24705470211035607. PubMed ID: 34377878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms.
    Nikolaidis A; Lancelotta R; Gukasyan N; Griffiths RR; Barrett FS; Davis AK
    J Affect Disord; 2023 Mar; 324():239-249. PubMed ID: 36584715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being.
    Moreton SG; Arena AFA; Foy Y; Menzies RE
    Death Stud; 2023; 47(10):1115-1126. PubMed ID: 36729996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey.
    Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Verroust V; Piolino P; Benyamina A
    J Psychoactive Drugs; 2024 Jul; ():1-12. PubMed ID: 38961652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada.
    Haeny AM; Lopez JA; Colón Grigas PA; Crouch MC; Davis AK; Williams M
    J Subst Use Addict Treat; 2023 Jun; 149():209035. PubMed ID: 37019336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.
    Williams MT; Davis AK; Xin Y; Sepeda ND; Grigas PC; Sinnott S; Haeny AM
    Drugs (Abingdon Engl); 2021; 28(3):215-226. PubMed ID: 34349358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Responses to Psychedelics: A Prospective Study.
    Haijen ECHM; Kaelen M; Roseman L; Timmermann C; Kettner H; Russ S; Nutt D; Daws RE; Hampshire ADG; Lorenz R; Carhart-Harris RL
    Front Pharmacol; 2018; 9():897. PubMed ID: 30450045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case analysis of long-term negative psychological responses to psychedelics.
    Bremler R; Katati N; Shergill P; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2023 Sep; 13(1):15998. PubMed ID: 37749109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey.
    Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Verroust V; Piolino P; Romeo B; Benyamina A
    Alcohol Alcohol; 2024 Jan; 59(2):. PubMed ID: 37981297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
    Nygart VA; Pommerencke LM; Haijen E; Kettner H; Kaelen M; Mortensen EL; Nutt DJ; Carhart-Harris RL; Erritzoe D
    J Psychopharmacol; 2022 Aug; 36(8):932-942. PubMed ID: 35924888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.
    Barbut Siva J; Barba T; Kettner H; Kuc J; Nutt DJ; Carhart-Harris R; Erritzoe D
    J Psychopharmacol; 2024 Feb; 38(2):145-155. PubMed ID: 38281075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
    Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.
    Herrmann Z; Earleywine M; De Leo J; Slabaugh S; Kenny T; Rush AJ
    J Psychoactive Drugs; 2023; 55(4):501-517. PubMed ID: 36127639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.
    Murphy R; Kettner H; Zeifman R; Giribaldi B; Kartner L; Martell J; Read T; Murphy-Beiner A; Baker-Jones M; Nutt D; Erritzoe D; Watts R; Carhart-Harris R
    Front Pharmacol; 2021; 12():788155. PubMed ID: 35431912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.